Centering discussion on a patient case of relapsed/refractory multiple myeloma, expert David Dingli, MD, PhD, reflects on the current treatment paradigm and evolving management strategies in this setting.
EP. 1: Patient Case: A 76-Year-Old Man with Pentarefractory Multiple Myeloma
David M. Dingli, MD, PhD, a hematologist at Mayo Clinic, as he discusses a challenging case of pentarefractory multiple myeloma in a 76-year-old patient and explores novel treatment options.
EP. 2: Immunologic Therapies in Multiple Myeloma: Expert Insights
An exploration of the landscape of immunologic therapies and alternative approaches for relapsed/refractory multiple myeloma, including bispecific antibodies, XPO1 inhibitors, venetoclax, and more.
EP. 3: Impact of Teclistamab on the Management of Relapsed/Refractory Multiple Myeloma
Expert perspective on teclistamab, a bispecific antibody, in the context of multiple myeloma treatment, discussing its potential benefits and associated considerations.
EP. 4: Talquetamab and Elranatamab: Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma
Insights into the use of bispecific antibodies, including talquetamab, and elranatamab, in treating relapsed/refractory multiple myeloma, discussing their efficacy and potential side effects.
EP. 5: Choosing Between CAR T and Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma
David M. Dingli, MD, PhD, discusses the advantages and considerations of CAR T-cell therapy versus bispecific antibodies for relapsed/refractory multiple myeloma, helping patients make informed treatment decisions.
EP. 6: Patient-Centered Approach to Managing Bispecific Antibody Therapy
The importance of patient education, remote monitoring, and infection prophylaxis in the safe administration of bispecific antibody therapy for relapsed/refractory multiple myeloma.
EP. 7: Navigating Unmet Needs and Challenges in Multiple Myeloma Treatment
EP. 8: Future Landscape: Collaboration for Patients With Relapsed/Refractory Multiple Myeloma
Discover how the treatment landscape for relapsed/refractory myeloma is evolving through collaboration between academic centers and community oncologists, offering patients access to innovative therapies and clinical trials.
2 Clarke Drive Cranbury, NJ 08512